A.O. Ospedale Niguarda Ca' Granda
Welcome,         Profile    Billing    Logout  
 3 Trials 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Siena, Salvatore
ETNA, NCT01822314 / 2012-003481-41: Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer

Checkmark ETNA trial in HER2-negative high-risk breast cancer
May 2016 - May 2016: ETNA trial in HER2-negative high-risk breast cancer
Completed
3
632
Europe, RoW
Abraxane, Nab-paclitaxel, Paclitaxel, No specific brand name
Fondazione Michelangelo
Breast Cancer
09/16
03/23
STARTRK-2, NCT02568267 / 2015-003385-84: Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Checkmark From STARTRK-2 trial in NTRK+ solid tumors
Oct 2019 - Oct 2019: From STARTRK-2 trial in NTRK+ solid tumors
Checkmark STARTRK-2 trial in NTRK+ solid tumors at ESMO 2018 [screenshot]
Oct 2018 - Oct 2018: STARTRK-2 trial in NTRK+ solid tumors at ESMO 2018 [screenshot]
Checkmark Integrated analysis of 3 trials (STARTRK-2, STARTRK-1, ALKA-372-001) in NTRK fusion-positive solid tumors
More
Active, not recruiting
2
534
Europe, Japan, US, RoW
Entrectinib, RXDX-101
Hoffmann-La Roche
Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Primary Brain Tumors, Renal Cell Carcinoma, Sarcomas, Salivary Gland Cancers, Adult Solid Tumor
12/24
04/25

Download Options